SCHEMBL5463185

SCHEMBL5463185

CCOC(=O)Cc1cc(Cl)c([N+](=O)[O-])cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.45
THRB P10828 1/20 0.44
LMNA P02545 3/20 0.43
PDGFRB P09619 1/20 0.42
FGFR1 P11362 1/20 0.42
PDGFRA P16234 1/20 0.42
FLT1 P17948 1/20 0.42
FGFR3 P22607 1/20 0.42
KDR P35968 1/20 0.42
ALDH1A1 P00352 2/20 0.42
VCAM1 P19320 1/20 0.41
MAPT P10636 2/20 0.41
GAA P10253 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
NPC1 O15118 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL358074 0.91 PDGFRB (0.48) POLBTHRBLMNAPDGFRBFGFR1
SCHEMBL15056289 0.87 CYP1A2 (0.45) POLBTHRBLMNAPDGFRBFGFR1
SCHEMBL4281268 0.85 MAPT (0.40) POLBTHRBLMNAPDGFRBFGFR1
SCHEMBL10652092 0.84 POLB (0.41) POLBTHRBLMNAALDH1A1VCAM1
SCHEMBL5459674 0.82 LMNA (0.40) THRBLMNAPDGFRBFGFR1PDGFRA
SCHEMBL11810881 0.81 KMT2A (0.43) MAPTGAAKMT2ATDP1
SCHEMBL11496405 0.81 POLB (0.43) POLBTHRBLMNAALDH1A1VCAM1
SCHEMBL19182419 0.79 SIGMAR1 (0.47) ALDH1A1VCAM1MAPTKMT2ANPC1
SCHEMBL4271172 0.79 POLB (0.51) POLBLMNAALDH1A1MAPTGAA
SCHEMBL29279220 0.79 TSHR (0.41) THRBLMNAPDGFRBFGFR1PDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7345179-B2 Process for producing pyrrolidine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-18 US disclosed
US-7345179-B2 Process for producing pyrrolidine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-18 US disclosed
US-20070149606-A1 Process for producing phenylacetic acid derivative DAIICHI PHARMACEUTICAL CO.,LTD. (JP) 2007-06-28 US disclosed
US-20070149606-A1 Process for producing phenylacetic acid derivative DAIICHI PHARMACEUTICAL CO.,LTD. (JP) 2007-06-28 US disclosed
US-20070149606-A1 Process for producing phenylacetic acid derivative DAIICHI PHARMACEUTICAL CO.,LTD. (JP) 2007-06-28 US disclosed
US-20070105935-A1 Process for producing pyrrolidine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-05-10 US disclosed
US-20070105935-A1 Process for producing pyrrolidine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-05-10 US disclosed
EP-1698611-A1 PROCESS FOR PRODUCING PHENYLACETIC ACID DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105935-A1 Process for producing pyrrolidine derivative ACSL4, ALDH18A1, LTA POLB 1369/4885THRB 2211/4885LMNA 1044/4885
US-20070149606-A1 Process for producing phenylacetic acid derivative UGT1A4, VPS4B, CYP3A4 POLB 1933/4885THRB 1132/4885LMNA 2676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.